Cited by 317Prostate Cancer Treatment and ResearchChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

Open access

Takeda, David Y., Spisák, Sándor, Seo, Ji-Heui, Bell, Connor, O’Connor, Edward, Korthauer, Keegan, Ribli, Dezső, Csabai, István, Solymosi, Norbert, Szállási, Zoltán, Stillman, David R., Cejas, Paloma, Qiu, Xintao, Long, Henry W., Tisza, Viktória, Nuzzo, Pier Vitale, Rohanizadegan, Mersedeh, Pomerantz, Mark M., Hahn, William C., Freedman, Matthew L.·2018·Cell

DOI 10.1016/j.cell.2018.05.037PMC PMC6046260

Open this paper in CoChat — free account Open PDF

Abstract

Increased androgen receptor (AR) activity drives therapeutic resistance in advanced prostate cancer. The most common resistance mechanism is amplification of this locus presumably targeting the AR gene. Here, we identify and characterize a somatically acquired AR enhancer located 650 kb centromeric to the AR. Systematic perturbation of this enhancer using genome editing decreased proliferation by suppressing AR levels. Insertion of an additional copy of this region sufficed to increase proliferation under low androgen conditions and to decrease sensitivity to enzalutamide. Epigenetic data generated in localized prostate tumors and benign specimens support the notion that this region is a developmental enhancer. Collectively, these observations underscore the importance of epigenomic profiling in primary specimens and the value of deploying genome editing to functionally characterize noncoding elements. More broadly, this work identifies a therapeutic vulnerability for targeting the AR and emphasizes the importance of regulatory elements as highly recurrent oncogenic drivers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2018.05.037

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications
Krueger, F., & Andrews, S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr167 · Cited by 5,275
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302

Flagged first, then by citations

Show all 55 references

Sorted by citations

Items 201–300 of 317

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer
Eickhoff, N., Bergman, A. M., & Zwart, W. T. (2022) · Endocrinology · doi:10.1210/endocr/bqac153 · Cited by 10
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Chen, X., Shao, Y., Wei, W., Zhu, S., Li, Y., Chen, Y., Li, H., Tian, H., Sun, G., Niu, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05366-8 · Cited by 10
Molecular Mechanisms of Castrate-Resistant Prostate Cancer
Kotamarti, S., Armstrong, A. J., Polascik, T. J., & Moul, J. W. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.07.005 · Cited by 9
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems
Bergom, H. E., Shabaneh, A., Day, A., Ali, A. A.-M., Boytim, E., Tape, S., Lozada, J. R., Shi, X., Kerkvliet, C. J. P., McSweeney, S. T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04795-1 · Cited by 9
Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate
He, Y., Johnson, D. T., Yang, J., Wu, H., You, S., Yoon, J., Lee, D., Kim, W. K., Aldahl, J., Le, V. L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0901-8 · Cited by 9
Metallic Cation-Mediated Entrapment of Nucleic Acids on Mesoporous Silica Surface: Application in Castration-Resistant Prostate Cancer
Maestas-Olguin, A., Olewine, M., Thabata, S., Ebode, J. T., Arcos, M., Krawchuck, J. A., Coker, E. N., BREARLEY, A. J., Xue, X., Watt, J. D., et al. (2023) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c01174 · Cited by 7
Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer
Semaan, K., Nawfal, R., Canniff, J., Savignano, H., Seo, J.-H., Siegmund, S., Wu, S. J., Rotow, J. K., Lee, G. M., Chehade, R. E. H., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01031-3 · Cited by 8
Self-citation
Chromatin accessibility analysis uncovers regulatory element landscape in prostate cancer progressionPreprint
Uusi-Mäkelä, J., Afyounian, E., Tabaro, F., Häkkinen, T., Lussana, A., Shcherban, A., Annala, M., Nurminen, R., Kivinummi, K. K., Tammela, T. L. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.08.287268 · Cited by 11
The Androgen Regulation of Matrix Metalloproteases in Prostate Cancer and Its Related Tumor Microenvironment
Sorrentino, C., D’Angiolo, R., Gentile, G., Giovannelli, P., Perillo, B., Migliaccio, A., Castoria, G., & Donato, M. D. (2023) · Endocrines · doi:10.3390/endocrines4020027 · Cited by 7
Mechanistic insights into steroid hormone-mediated regulation of the androgen receptor gene
Gillen, A. D., Hunter, I., Ullner, E., & McEwan, I. J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304183 · Cited by 7
Roles of CDK12 mutations in PCa development and treatment
Jiang, C., Hong, Z., Liu, S., Hong, Z., & Dai, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189247 · Cited by 8
A HOTAIR-associated super-enhancer orchestrates glioblastoma malignancy via MEST
Li, P., Yang, Y., Luan, C., Wang, W., Jiang, Y., Zhao, Z., Wang, W., Zhao, Y., Bai, Y., Liu, M., et al. (2025) · Oncogenesis · doi:10.1038/s41389-025-00551-8 · Cited by 7
Prostate cancer cells converge to an inflammatory-like state upon metastatic dissemination
Keshavarzian, T., Furlano, K., Grillo, G., Mout, L., Arlidge, C., Hasan, F., Nand, A., Mikutenaite, M., Karadoulama, E., Goyal, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67856-5 · Cited by 7
Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies
Weiss, S., Lamy, P., Rusan, M., Nørgaard, M., Ulhøi, B. P., Knudsen, M., Kassentoft, C. G., Farajzadeh, L., Jensen, J. B., Pedersen, J. S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34949 · Cited by 9
Sequence of events in prostate cancer
Cotter, K. A., & Rubin, M. A. (2018) · Nature · doi:10.1038/d41586-018-06029-5 · Cited by 7
Beyond the coding genome non-coding mutations and cancer
Notani, D. (2020) · Frontiers in bioscience · doi:10.2741/4879 · Cited by 7
A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery
Tian, J., Chi, C., Bian, G., Guo, F., Wang, X., & Yu, B. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13499 · Cited by 7
Epigenetic Coregulation of Androgen Receptor Signaling
Fernandes, R. C., Leach, D. A., & Bevan, C. L. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_16 · Cited by 7
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers
Chrenková, E., Študentová, H., Holá, K., Kahounová, Z., Hendrychová, R., Souček, K., & Bouchal, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394292 · Cited by 6
Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution
Furlano, K., Keshavarzian, T., Biernath, N., Fendler, A., Santis, M. D., Weischenfeldt, J., & Lupien, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.35327 · Cited by 6
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer
Halabi, S., Guo, S., Luo, B., Yu, C., Knutson, T. P., Kobilka, A., Lyman, J., Beltran, H., Antonarakis, E. S., Galsky, M. D., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.011 · Cited by 9
Profiling of Androgen-Dependent Enhancer RNAs Expression in Human Prostate Tumors: Search for Malignancy Transition Markers
Nishimura, K., Mori, J., Sawada, T., Nomura, S., Kouzmenko, A., Yamashita, K., Kanemoto, Y., Kurokawa, T., Hayakawa, A., Tokiwa, S., et al. (2021) · Research and Reports in Urology · doi:10.2147/rru.s328661 · Cited by 6
Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications
Kneppers, J., Bergman, A. M., & Zwart, W. T. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_15 · Cited by 6
Genetic and Epigenetic Dysregulation of Transcriptional Enhancers in Cancer
Botten, G. A., & Xu, J. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060324-114306 · Cited by 7
SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression
Eteleeb, A. M., Quigley, D. A., Zhao, S. G., Pham, D., Yang, R., Dehm, S. M., Luo, J. R., Feng, F. Y.-C., Dang, H. X., & Maher, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71168-7 · Cited by 6
Modeling tissue-specific breakpoint proximity of structural variations from whole-genomes to identify cancer drivers
Martinez‐Fundichely, A., Dixon, A., & Khurana, E. (2022) · Nature Communications · doi:10.1038/s41467-022-32945-2 · Cited by 5
Clinical Implementation of a Noninvasive, Multi-Analyte Droplet Digital PCR Test to Screen for Androgen Receptor Alterations
Stitz, R., Stoiber, F., Silye, R., Vlachos, G., Andaloro, S., Rebhan, E.-M., Dunzinger, M., Pühringer, F., Gallo, C., Heliebi, A. E., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.02.009 · Cited by 6
GAS1RR, an immune-related enhancer RNA, is related to biochemical recurrence-free survival in prostate cancer
Xiong, Z.-Z., Ge, Y., Xiao, J., Wang, Y., Li, L., Ma, S., Lan, L., Liu, B., Qin, B.-L., Luan, Y., et al. (2022) · Experimental biology and medicine · doi:10.1177/15353702221131888 · Cited by 6
Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
Peinetti, N., Bilušić, M., & Burnstein, K. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci165357 · Cited by 6
Systems-level liquid biopsy in advanced prostate cancer
Lyman, J. A., & Dehm, S. M. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0274 · Cited by 5
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
Leone, G., Orlando, F., Dutey‐Magni, P., Vainauskas, O., Grist, E., Ciani, Y., Lall, S. K., Thakali, S., Wingate, A., Wetterskog, D., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.7051 · Cited by 5
Triple-arm androgen blockade for advanced prostate cancer: a review
Desai, M. H., Parsi, M., & Potdar, R. R. (2021) · Medical Oncology · doi:10.1007/s12032-021-01520-y · Cited by 5
Dinucleotide tag‐based parallel reporter gene assay method enables efficient identification of regulatory mutations
Ren, N., Li, B., Liu, Q., Yang, L., Liu, X., & Huang, Q. (2021) · Biotechnology Journal · doi:10.1002/biot.202100341 · Cited by 5
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
Virtanen, T., Kwan, E. M., Parekh, K., Bacon, J. V. W., Huang, C.-C. F., Yu, I. P. L., Ryyppö, L., Bernales, C. Q., Donnellan, G., Tam, C. S. L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1236 · Cited by 5
Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions
Guo, J., Wei, Z., Jia, T., Wang, L., Nama, N., Liang, J., Liao, X., Liu, X., Gao, Y., Liu, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04429-4 · Cited by 4
Small-molecule disruption of androgen receptor–dependent chromatin clusters
Kohrt, S. E., Novak, E. J., Tapadar, S., Wu, B., Strope, J. D., Asante, Y., Kim, H., Chang, M. S., Gurdak, D., Khalil, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406239121 · Cited by 4
Response to: Comment on “circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer”
Cai, J., Chen, Z., & Zuo, X. (2019) · Disease Markers · doi:10.1155/2019/9356804 · Cited by 4
Functional Screenings Identify Regulatory Variants Associated with Breast Cancer Susceptibility
Ren, N., Li, Y., Xiong, Y., Li, P., Ren, Y., & Huang, Q. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43030124 · Cited by 4
Epigenetic Regulation by Androgen Receptor in Prostate Cancer
Takayama, K. (2018) · OBM Genetics · doi:10.21926/obm.genet.1804047 · Cited by 4
Evolution of the prostate cancer genome towards resistance
Lorenzin, F., & Demichelis, F. (2019) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2019.01 · Cited by 4
Cis -regulatory Element Hijacking by Structural Variants Overshadows Higher-Order Topological Changes in Prostate CancerPreprint
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.425333 · Cited by 4
Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibitionPreprint
Wilkinson, S. C., Ku, A. T., Lis, R. T., King, I. M., Low, D., Trostel, S. Y., Bright, J. R., Terrigino, N. T., Baj, A., Fenimore, J. M., et al. (2024) · medRxiv · doi:10.1101/2024.02.09.24302395 · Cited by 4
Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerPreprint
Li, S., Song, K., Sun, H., Tao, Y., Huang, A. J. Y., Bhatia, V., Hanratty, B. P., Patel, R. A., Long, H. W., Morrissey, C. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.12.637904 · Cited by 4
Self-citation
Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance
Gao, S., Patten, N. D., & Cai, C. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.003 · Cited by 4
Genetic disruption of the baculum compromises the ability of male mice to copulate
Ghione, C., Schultz, N. G., Park, S., Menke, D. B., & Dean, M. D. (2025) · PLoS Genetics · doi:10.1371/journal.pgen.1011787 · Cited by 3
Discovery of Novel Thiohydantoin Derivatives as Full Antagonists and Efficient Degraders of Androgen Receptor
Chang, X., Zhang, D., Qu, F., Xie, Y., Chen, T., Zhang, Y., Du, Q., Bian, J., Li, Z., Wang, J., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115490 · Cited by 3
Enhancer in cancer pathogenesis and treatment
Sun, Z., Fan, J., Dang, Y., & Zhao, Y. (2023) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0313 · Cited by 4
It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective
Zaalberg, A., Pottendorfer, E., Zwart, W. T., & Bergman, A. M. (2024) · Cancers · doi:10.3390/cancers16020294 · Cited by 3
HYENA detects oncogenes activated by distal enhancers in cancer
Yu, A., Yesilkanal, A. E., Thakur, A., Wang, F., Yang, Y., Phillips, W., Wu, X., Muir, A., He, X., Spitz, F., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae646 · Cited by 2
Bavdegalutamide (ARV-110): a potent PROTAC androgen receptor degrader for the treatment of metastatic-castration resistant prostate cancer
Ma, L., & Han, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00020-0 · Cited by 3
A dinucleotide tag-based parallel reporter gene assay methodPreprint
Ren, N., Li, B., Liu, Q., Yang, L., Liu, X., & Huang, Q. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.29.450267 · Cited by 3
Sensitive detection of copy number alterations in samples with low circulating tumor DNA fractionPreprint
Mayrhofer, M., Bergström, R., Chellappa, V., Kotsalaynen, A., Murugan, S. K., Crippa, A., Laere, B. D., Urtishak, K. A., Sørensen, K. D., Garg, K., et al. (2024) · medRxiv · doi:10.1101/2024.05.04.24306860 · Cited by 3
A chromatin fiber model explains cell-free DNA fragmentation signatures of active regulatory elementsPreprint
Yang, A., Lee, G. G., Chhetri, S. B., Chehade, R. E. H., Gulati, G. S., Pandey, M., Fu, D., Kim, Y.-N., Sotudian, S., Savignano, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.06.686988 · Cited by 5
Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer
Xu, P., Qu, H., Yang, J. C., Fan, W., Zhao, J., Tang, M., Wang, L., Nip, C., Li, H., Gao, A. C., et al. (2025) · Cancers · doi:10.3390/cancers17193187 · Cited by 2
Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer
Saker, Z., Rizk, M., & Nabha, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00004-x · Cited by 2
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
Miyahira, A. K., Kamran, S. C., Jamaspishvili, T., Marshall, C. H., Maxwell, K. N., Parolia, A., Zorko, N. A., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24721 · Cited by 2
Capped nascent RNA sequencing reveals novel therapy-responsive enhancers in prostate cancerPreprint
Cotter, K. A., Shah, S. R., Paramo, M. I., Lou, S., Li, Y., Rubin, P. D., Chen, Y., Gerstein, M., Rubin, M. A., & Yu, H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.08.487666 · Cited by 2
Chromatin interaction maps identify oncogenic targets of enhancer duplications in cancerPreprint
Song, Y., Li, F., Wang, S., Wang, Y., Lai, C., Chen, L., Jiang, N., Li, J., Chen, X., Bailey, S. D., et al. (2024) · Genome Research · doi:10.1101/gr.278418.123 · Cited by 2
Promoter-centric gene regulation in drug-resistant cancerPreprint
Kameswaran, V., Paul, S., Le, D. X., Hoover, J., Zhao, L., Guarnaccia, A. D., Hagenbeek, T. J., Lund, J. M., Xavier‐Magalhães, A., Shi, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.639310 · Cited by 2
The Androgen Receptor: Key to Testosterone Function and Androgen Sensitivity
Paakinaho, V., & Palvimo, J. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_12 · Cited by 1
Regulation of androgen receptor expression by enhancer elements in prostate cancer
Khadka, S., Jeon, H., Hussain, A., & Qi, J. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01624-9 · Cited by 1
Promoter reinforcement supports transcriptional resilience in drug-resistant cancer
Kameswaran, V., Paul, S., Le, D., Guarnaccia, A. D., Hoover, J., Chen, L., Hagenbeek, T. J., Shi, M., Zhao, L., Lund, J. M., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01829-0 · Cited by 4
Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases
Hsiao, J. J., Smits, M. M., Ng, B. H., Lee, J., & Wright, M. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-01554-2 · Cited by 1
Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308
Nouruzi, S., Johnson, F. D., Kumar, S., Sivak, O., Tabrizian, N., Koistinaho, M., Muona, A., & Zoubeidi, A. (2024) · Oncology Reports · doi:10.3892/or.2024.8791 · Cited by 1
Unearthing a Prostate Cancer cfDNA Signature that “Stems” from AR Alterations
Nawfal, R., Chehade, R. E. H., & Berchuck, J. E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2849 · Cited by 1
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey‐Holden Prostate Cancer Academy Meeting
Miyahira, A. K., Sharifi, M. N., Chesner, L. N., El-Kenawi, A., Haas, R., Sena, L. A., Tewari, A. K., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24826 · Cited by 1
Discovery of Easily Synthesizable 4, 4‐Dimethylimidazolidin‐2‐ones as Potent Androgen Receptor Antagonists for Prostate Cancer
Yaragani, M., Yadlapalli, P., Raghavan, S. S., Giridhar, T., Mandava, V. B. R., Singh, R. V., Kottapalli, R. P., & Saravanan, C. (2021) · ChemistrySelect · doi:10.1002/slct.202101546 · Cited by 1
Genome-wide analyses of transcription factors and co-regulators across seven cohorts identified reduced PPARGC1A expression as a driver of prostate cancer progressionPreprint
Manjunath, S., Wani, S. A., Long, M. D., Leach, D. A., Mathé, E. A., Bevan, C. L., & Campbell, M. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.12.091066 · Cited by 1
H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic StrategiesPreprint
Terranova, C. J., Maitituoheti, M., Raman, A. T., Tang, M., Anvar, N. E., Ghosh, A. K., Amin, S. B., Schulz, J. E., Orouji, E., Giancotti, F. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.02.458625 · Cited by 1
Dosage Amplification Dictates Oncogenic Regulation by the NKX2-1 Lineage Factor in Lung AdenocarcinomaPreprint
Pulice, J. L., & Meyerson, M. M. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4612965 · Cited by 1
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancerPreprint
Poluben, L., Nouri, M., Liang, J., Varkaris, A. S., Ersoy-Fazlioglu, B., Voznesensky, O. S., Lee, I. I., Qiu, X., Cato, L., Seo, J.-H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.10.575110 · Cited by 1
Self-citation
Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerPreprint
Li, S., Song, K., Sun, H., Tao, Y., Huang, A. J. Y., Bhatia, V., Hanratty, B. P., Patel, R. A., Long, H. W., Morrissey, C. M., et al. (2025) · eLife · doi:10.7554/elife.106511.1 · Cited by 1
Self-citation
Rewiring Oncogenic Transcriptional Complexes with Domain-ALTerAtion Chimeras (DALTACs) in Prostate CancerPreprint
Luo, J., Yang, J., Tien, J. C.-Y., Wang, M., Das, S., Wang, X., Young, E., Tošović, J., Mannan, R., Xiang, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.24.720638 · Cited by 1
Epigenetic Rewiring of Enhancer–Promoter Interactions in Cancer: Mechanisms and Therapeutic Implications
Choppavarapu, L., Nosirov, B., Kahn, M., & Jin, V. X. (2026) · Cancers · doi:10.3390/cancers18213416
New genomic drivers identified
Bradley, C. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0057-2
AR Gain: Resistance Mechanism or Measure of Tumor Burden?
VanderWeele, D. J. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00315
Use of miRNA as a Biomarker in Prostate Cancer and New Approaches
Aslan, E. S. (2020) · Turkish Journal of Oncology · doi:10.5505/tjo.2019.2202
Convergent mutations in tissue-specific regulatory regions reveal novel cancer driversPreprint
Sinnott-Armstrong, N., Seoane, J. A., Sallari, R. C., Pritchard, J. K., Curtis, C. N., & Snyder, M. P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.21.239954
Phased Whole-Genome Detection and Analysis of Structural Variants of Invasive Ductal and Lobular Breast Cancer Cell Lines
Fey, E. E. (2019)
Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer
Saraç, H., Cherkasov, A. R., & Lack, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00007-3
Identification of a novel p52-regulated long noncoding RNA in multiple myeloma
Ang, D. A. (2020) · doi:10.32657/10356/145120
Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole Genome SequencingPreprint
Pham, M., Gupta, H., Gupta, A. K., Vaghasia, A. M., Skaist, A. M., Garrison, M. A., Coulter, J. B., Haffner, M. C., Isaacs, W. B., Wheelan, S. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.09.455584
Decoding androgen receptor inhibitor resistance in prostate cancer
Palit, S. A. L. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1350
Faculty Opinions recommendation of Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
Bevan, C. L., & Constantin, T. A. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738340952.793583202
Discovery of Novel Thiohydantoin Derivatives as Full Antagonists and Efficient Degraders of Androgen ReceptorPreprint
Zhang, D., Chen, T., Zhang, Y., Li, Y., Wang, M., Wu, H., Qiu, Z., Bian, J., Li, Z., Wang, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4173282
Treatment-mediated selection of lethal prostate cancer clones defined by copy number architecturesPreprint
Hasan, A. M. M., Cremaschi, P., Wetterskog, D., Jayaram, A., Wong, S. Q., Williams, S., Pasam, A., Trigos, A., Trujillo, B., Grist, E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.506183
A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma
Li, Q., Xiao, X., Chen, B., Song, G., Zeng, K., Li, B., Miao, J., Liu, C., Luan, Y., & Liu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964838
Mechanism and Treatment of Drug Resistance in Castration-Resistant Prostate Cancer Caused by Glucocorticoid Receptors
李, 晨. (2023) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2023.111004
Data from Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition
Annala, M., Taavitsainen, S., Khalaf, D. J., Vandekerkhove, G. R., Beja, K., Sipola, J., Warner, E. W., Herberts, C., Wong, A., Fu, S. Y. F., et al. (2023) · doi:10.1158/1078-0432.c.6530771
Data from A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer
Rodríguez, Y., Unno, K., Truica, M. I., Chalmers, Z. R., Yoo, Y. A., Vatapalli, R. J., Sagar, V., Yu, J., Lysy, B., Hussain, M., et al. (2023) · doi:10.1158/0008-5472.c.6513723.v1
Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2023) · doi:10.1158/0008-5472.c.6513724.v1
Data from Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance
Ghildiyal, R., Sawant, M., Renganathan, A., Mahajan, K. N., Kim, E. H., Luo, J. R., Dang, H. X., Maher, C. A., Feng, F. Y.-C., & Mahajan, N. P. (2023) · doi:10.1158/0008-5472.c.6513456.v1
Supplementary Data from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2023) · doi:10.1158/0008-5472.22430878
Supplementary Table 2 from Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K. J., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2023) · doi:10.1158/0008-5472.22430854
Data from Enhancer Coamplification and Hijacking Promote Oncogene Expression in Liposarcoma
Liu, T., Wang, J., Yang, H., Jin, Q., Wang, X., Fu, Y., Luan, Y., Wang, Q., Youngblood, M. W., Lu, X., et al. (2023) · doi:10.1158/0008-5472.c.6626138.v1
Utilizing a dual endogenous reporter system to identify functional regulators of aberrant stem cell and differentiation activity in colorectal cancerPreprint
Spisák, S., Chen, D. J., Likasitwatanakul, P., Doan, K. T., Li, Z., Bala, P., Vízkeleti, L., Tisza, V., Silva, P. D., Giannakis, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.21.545895
Self-citation
Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer
Fu, B., Wang, L., Jia, T., Wei, Z., Nama, N., Liang, J., Liao, X., Liu, X., Gao, Y., Liu, X., et al. (2023) · The Prostate · doi:10.1002/pros.24603
The Molecular Biology of Prostate Cancer: Diagnosis, Resistance and Virulence
Thompson, R., Essa, S., & Marcus, M. (2024) · SciBase oncology. · doi:10.52768/oncology/1012
Systemic genome-epigenome analysis captures the lineage specificity and functional significance for MYB associated super-enhancer in gastrointestinal adenocarcinomaPreprint
Li, F., Wang, S., Chen, L., Jiang, N., Chen, X., & Li, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.11.622904
Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerPreprint
Li, S., Song, K., Sun, H., Tao, Y., Huang, A. J. Y., Bhatia, V., Hanratty, B. P., Patel, R. A., Long, H. W., Morrissey, C. M., et al. (2025) · eLife · doi:10.7554/elife.106511
Self-citation

Authors: Takeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., Stillman, D. R., Cejas, P., Qiu, X., Long, H. W., Tisza, V., Nuzzo, P. V., Rohanizadegan, M., Pomerantz, M. M., Hahn, W. C., & Freedman, M. L.
Affiliations: Broad Institute (US)
Dana-Farber Cancer Institute (US)
Harvard University (US)
Eötvös Loránd University (HU)
University of Veterinary Medicine (HU)
Semmelweis University (HU)
Boston Children's Hospital (US)
Corresponding author: Freedman, Matthew L.
ORCID: Takeda, David Y.
Spisák, Sándor
Seo, Ji-Heui
Bell, Connor
O’Connor, Edward
Korthauer, Keegan
Ribli, Dezső
Csabai, István
Solymosi, Norbert
Szállási, Zoltán
Cejas, Paloma
Qiu, Xintao
Long, Henry W.
Tisza, Viktória
Nuzzo, Pier Vitale
Rohanizadegan, Mersedeh
Pomerantz, Mark M.
Hahn, William C.
Freedman, Matthew L.
Venue: Cell
Publisher: Elsevier BV
Published: 2018-07
Volume: 174
Issue: 2
Pages: 422-432.e13
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2018.05.037
PMC: PMC6046260
OpenAlex: W2808687910
Cited by: 317
References: 55
Citations by year: 2026: 14 · 2025: 31 · 2024: 44 · 2023: 47 · 2022: 41 · 2021: 54 · 2020: 44 · 2019: 32 · 2018: 10
FWCI: 26.37
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 376 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Prostate Cancer Foundation Challenge Award
NIH (R01GM107427, R01CA193910, K08CA218530, R01HG005220, U01 CA176058)
National Research, Development and Innovation Fund of Hungary Project (FIEK_16-1-2016-0005)
Novo Nordisk Foundation Interdisciplinary Synergy Programme (NNF15OC0016584)
European Social Fund (EFOP-3.6.3-VEKOP-16-2017-00005)
Breast Cancer Research Foundation (BCRF-17-156)
H.L. Snyder Medical Research Foundation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: androgen receptor, advanced prostate cancer, treatment resistance, enzalutamide resistance, non-coding regulatory elements, genome editing, epigenetic profiling, oncogenic drivers
MeSH terms: Gene Editing, Acetylation, Adult, Aged, Antineoplastic Agents, Benzamides, Cell Survival, Enhancer Elements, Genetic, Histones, Humans, Male, Middle Aged, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Receptors, Androgen, DNA Methylation, Cell Line, Tumor, CRISPR-Cas Systems, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks